title: Which postoperative combined therapy results in the best prognosis: radiochemocytokine therapy or aggressive chemotherapy?
abstract: The recurrence of esophageal cancer involving regional nodes, even in patients who have undergone curative surgery, often takes place within three years after surgery. Thus, a new multidisciplinary treatment including cytokines or aggressive chemotherapy with active nutritional support to improve the prognosis in cancer of the thoracic esophagus has been adopted.
authors.affiliation: Second Department of Surgery, Tohoku University School of Medicine, Sendai, Japan.
authors.forename: T
authors.initials: T
authors.lastname: Nishihira
authors.forename: K
authors.initials: K
authors.lastname: Hirayama
authors.forename: T
authors.initials: T
authors.lastname: Akaishi
authors.forename: R
authors.initials: R
authors.lastname: Shineha
authors.forename: A
authors.initials: A
authors.lastname: Okayama
authors.forename: S
authors.initials: S
authors.lastname: Mori
mesh_terms: D000971:Antineoplastic Combined Chemotherapy Protocols / Q000627:therapeutic use*; D003131:Combined Modality Therapy; D004938:Esophageal Neoplasms / Q000628:therapy*; D006801:Humans; D016898:Interferon-alpha / Q000008:administration & dosage*; D007376:Interleukin-2 / Q000008:administration & dosage*; D011182:Postoperative Care; D011379:Prognosis; D012189:Retrospective Studies; D014409:Tumor Necrosis Factor-alpha / Q000008:administration & dosage*
chemical_list: D016898:Interferon-alpha; D007376:Interleukin-2; D014409:Tumor Necrosis Factor-alpha